Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Other Events

ME Staff 8-k
-
0

Stemline Therapeutics,Inc. (NASDAQ:STML) Files An 8-K Other Events
Item 8.01 Other Events.

On October31, 2017, Stemline Therapeutics,Inc. announced that the pivotal Phase 2 trial of SL-401 in blastic plasmacytoid dendritic cell neoplasm (BPDCN) has met its primary endpoint.

A copy of such press release is being furnished as Exhibit99.1 to this report.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

The following exhibit is furnished herewith:

Exhibit Number

Description

99.1

Press release issued by Stemline Therapeutics,Inc., dated October31, 2017.


STEMLINE THERAPEUTICS INC Exhibit
EX-99.1 2 a17-24912_1ex99d1.htm EX-99.1 Exhibit 99.1     Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint   October 31,…
To view the full exhibit click here

About Stemline Therapeutics,Inc. (NASDAQ:STML)

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.